Loading...
NPI 1053721373 · Vestavia, AL · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Taustin Laboratories is a clinical medical laboratory provider located in Vestavia, Alabama. This profile covers 17 Medicare and 40 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Taustin Laboratories |
| Address | 2868 Acton Rd Ste 207 |
| City | Vestavia |
| State | AL |
| ZIP | 35243 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | May 8, 2014 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $37M |
| Medicare | $54.1K |
This provider is overwhelmingly Medicaid-focused: reported lifetime Medicaid revenue is $37M compared with $54.1K in Medicare, indicating Medicaid is the de facto primary payer and the dominant source of clinical volume and revenue for the operation. The disparity suggests the lab’s business model and capacity are organized around high-volume public health and community testing contracts rather than fee-for-service Medicare diagnostics.
Medicare revenue is concentrated in a small set of infectious-disease and susceptibility tests: the top three Medicare codes (87186, U0003, 87502) account for 49.7% of the provider’s total Medicare revenue. Code-level detail shows 87186 contributes $11.2K (21.0% of Medicare revenue), U0003 $8.1K (15.2%), and 87502 $7.2K (13.6%), so antibiotic susceptibility testing and respiratory/viral nucleic acid assays drive nearly half of the modest Medicare book of business.
Medicaid revenue is highly concentrated in a few high-throughput molecular assays: the top three Medicaid codes (87798, 87633, U0003) make up 60.6% of the provider’s Medicaid revenue. The single largest Medicaid code is 87798 at $10.4M (28.4%), followed by 87633 at $5.9M (16.2%) and U0003 at $5.8M (15.9%), reflecting major reliance on amplified-probe/multiplex infectious-agent testing panels.
Service-line implication: the code mix indicates a clinical laboratory focused on molecular infectious-disease testing and large-scale respiratory/COVID diagnostics (notably U0003, U0005, 87633, 87502 and 87798) with supporting microbiology for susceptibility work (87186) and some definitive drug-testing capability (G0480/G0483). This combination is consistent with a lab that operates high-throughput nucleic-acid testing workflows and maintains both molecular and conventional microbiology services to support public health and outpatient testing needs.
Competitive standing in Medicaid is strong for respiratory and COVID-related testing: 87798 ranks #3 of 57 in-state (96th percentile), 87633 ranks #4 of 98 in-state (97th percentile), and U0003 ranks #3 of 65 in-state (97th percentile), with 87502 at #1 of 112 in-state (100th percentile; labeled an extreme outlier, far above typical state volume for this code). Those ranks and large claim counts (e.g., 76.1K claims for 87798 and 106.2K claims for U0003) indicate this provider is a major in-state source for amplified-probe and multiplex respiratory testing.
By contrast, the provider’s Medicare footprint is modest overall despite relatively high national standing on select codes: 87186 ranks #193 of 2821 nationally (93th percentile) and 87502 ranks #289 of 3547 nationally (92th percentile), showing above-average national placement for antibiotic susceptibility and certain respiratory assays, but total Medicare revenue ($54.1K) remains immaterial compared with Medicaid. This pattern implies the lab is a strong state-level player for Medicaid testing while remaining a limited contributor to national Medicare volumes.
Several Medicaid codes are flagged as statistical outliers or notably above typical state volume, reinforcing the lab’s specialization and scale in particular test lines: 87502 and 87634 are described as "extreme outlier, far above typical state volume for this code," while 87640, 87635 and 87506 are described as "notably above typical state volume." These labels, together with the code-level revenues and claim counts, point to concentrated high-capacity workflows for respiratory and pathogen panels.
The provider has an established operational tenure with NPI enumeration on 2014-05-08 (~12 years ago), supporting a sustained presence in the market that aligns with the large Medicaid claim volumes and the infrastructure needed for high-throughput molecular testing. Longevity plus the Medicaid-dominant revenue profile suggests the lab has built scale and payer relationships primarily within the state public-payer ecosystem.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
17 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87186 | The lab analyst performs the technical steps to evaluate a culture isolate’s susceptibility, or sensitivity, to multiple antimicrobial agents, commonly called antibiotics, by observing growth of the… | 1,400 | $10 | $11.2K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 110 | $70 | $8.1K |
| 87502 | The lab analyst performs a test to determine the presence of multiple types or subtypes of influenza virus through nucleic acid detection using multiplex amplified probe technique and possibly… | 80 | $90 | $7.2K |
| 87500 | The lab analyst performs a test for vancomycin resistance in an infectious organism’s nucleic acid using amplified probe technique. VRE, vancomycin resistant enterococcus, is the most common organism… | 130 | $30 | $4.5K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 30 | $110 | $3.2K |
| 87486 | The lab analyst performs a test for Chlamydia pneumoniae using amplified nucleic acid probe technique. Chlamydia pneumoniae also known as TWAR, Taiwan Acute Respiratory agent, commonly causes mild… | 90 | $30 | $2.9K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 100 | $20 | $2.4K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 40 | $60 | $2.2K |
| 87640 | The lab analyst performs the technical lab test to look for Staphylococcus aureus nucleic acid using an amplified probe technique. | 60 | $30 | $2K |
| 87581 | The lab analyst performs a test for Mycoplasma pneumonia, a bacteria, using amplified nucleic acid probe technique. | 50 | $30 | $1.8K |
Showing 1–10 of 17
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 17 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
40 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 76,050 | $140 | $10.4M |
| 87633 | The lab analyst performs a test to identify a respiratory virus using amplified nucleic acid probe technique. He may also use a multiplex reverse transcription technique. The provider does this for… | 31,570 | $190 | $5.9M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 106,230 | $60 | $5.8M |
| 87502 | The lab analyst performs a test to determine the presence of multiple types or subtypes of influenza virus through nucleic acid detection using multiplex amplified probe technique and possibly… | 58,310 | $40 | $2.4M |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 20,360 | $90 | $1.8M |
| 87651 | The lab analyst performs a test for the bacteria Streptococcus, group A, using amplified nucleic acid probe technique. Strep A commonly causes acute pharyngitis, or strep throat. | 69,000 | $20 | $1.7M |
| 87581 | The lab analyst performs a test for Mycoplasma pneumonia, a bacteria, using amplified nucleic acid probe technique. | 58,160 | $20 | $1.4M |
| 87634 | The lab analyst performs a test for respiratory syncytial virus (RSV) antigen detection using amplified nucleic acid probe technique. | 39,840 | $20 | $876.4K |
| 87640 | The lab analyst performs the technical lab test to look for Staphylococcus aureus nucleic acid using an amplified probe technique. | 42,180 | $20 | $801.4K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 9,040 | $90 | $777.3K |
Showing 1–10 of 40
How this provider's Medicaid billing volume and revenue compare to other Alabama providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Alabama median
40 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 3 | 60 | 1,260 | $60 | $1.2M |
| 87633 | The lab analyst performs a test to identify a respiratory virus using amplified nucleic acid probe technique. He may also use a multiplex reverse transcription technique. The provider does this for… | 4 | 100 | 470 | $130 | $1.2M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 3 | 70 | 380 | $60 | $893.8K |
| 87507 | The lab analyst performs a test to detect 12 to 25 types or subtypes of a pathogen, such as Clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia, that affects the gastrointestinal… | 5 | 10 | 1,020 | $110 | $784.5K |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 17 | 40 | 450 | $20 | $591.3K |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 14 | 40 | 460 | $20 | $584.1K |
| 87661 | The lab analyst performs a test for Trichomonas vaginalis using nucleic acid amplified probe technique. | 6 | 40 | 1,540 | $10 | $397.4K |
| 87581 | The lab analyst performs a test for Mycoplasma pneumonia, a bacteria, using amplified nucleic acid probe technique. | 3 | 40 | 1,440 | $20 | $372.1K |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 5 | 90 | 500 | $40 | $303.6K |
| 87486 | The lab analyst performs a test for Chlamydia pneumoniae using amplified nucleic acid probe technique. Chlamydia pneumoniae also known as TWAR, Taiwan Acute Respiratory agent, commonly causes mild… | 4 | 40 | 2,000 | $20 | $273.5K |
Showing 1–10 of 40
Other providers in the same ZIP code as Taustin Laboratories, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.